| Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2117 | 2003 |
| Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients FJ Torriani, M Rodriguez-Torres, JK Rockstroh, E Lissen, ... New England Journal of Medicine 351 (5), 438-450, 2004 | 1698 | 2004 |
| Monkeypox virus infection in humans across 16 countries—April–June 2022 JP Thornhill, S Barkati, S Walmsley, J Rockstroh, A Antinori, LB Harrison, ... New England Journal of Medicine 387 (8), 679-691, 2022 | 1688 | 2022 |
| Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of … AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, O Degen, ... The Lancet 393 (10189), 2428-2438, 2019 | 1053 | 2019 |
| Maraviroc for previously treated patients with R5 HIV-1 infection RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ... New England Journal of Medicine 359 (14), 1429-1441, 2008 | 914 | 2008 |
| Raltegravir with optimized background therapy for resistant HIV-1 infection RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ... New England Journal of Medicine 359 (4), 339-354, 2008 | 908 | 2008 |
| Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans U Salzer, HM Chapel, ADB Webster, Q Pan-Hammarström, ... Nature genetics 37 (8), 820-828, 2005 | 800 | 2005 |
| Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 G Fätkenheuer, AL Pozniak, MA Johnson, A Plettenberg, S Staszewski, ... Nature medicine 11 (11), 1170-1172, 2005 | 663 | 2005 |
| Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection N Qurishi, C Kreuzberg, G Lüchters, W Effenberger, B Kupfer, ... The Lancet 362 (9397), 1708-1713, 2003 | 635 | 2003 |
| Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials PE Sax, KM Erlandson, JE Lake, GA Mccomsey, C Orkin, S Esser, ... Clinical Infectious Diseases 71 (6), 1379-1389, 2020 | 607 | 2020 |
| Late presentation of HIV infection: a consensus definition A Antinori, T Coenen, D Costagiola, N Dedes, M Ellefson, J Gatell, ... HIV medicine 12 (1), 61-64, 2011 | 606 | 2011 |
| Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ... New England Journal of Medicine 359 (4), 355-365, 2008 | 605 | 2008 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 578 | 2008 |
| Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy JK Rockstroh, A Mocroft, V Soriano, C Tural, MH Losso, A Horban, O Kirk, ... The Journal of infectious diseases 192 (6), 992-1002, 2005 | 549 | 2005 |
| Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection M Altfeld, MM Addo, ES Rosenberg, FM Hecht, PK Lee, M Vogel, GY Xu, ... Aids 17 (18), 2581-2591, 2003 | 480 | 2003 |
| Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel V Soriano, M Puoti, M Sulkowski, A Cargnel, Y Benhamou, M Peters, ... Aids 21 (9), 1073-1089, 2007 | 464 | 2007 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 444 | 2010 |
| Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir … E DeJesus, JK Rockstroh, K Henry, JM Molina, J Gathe, S Ramanathan, ... The Lancet 379 (9835), 2429-2438, 2012 | 443 | 2012 |
| Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men T van de Laar, O Pybus, S Bruisten, D Brown, M Nelson, S Bhagani, ... Gastroenterology 136 (5), 1609-1617, 2009 | 430 | 2009 |
| Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label … JK Rockstroh, M Nelson, C Katlama, J Lalezari, J Mallolas, M Bloch, ... The lancet HIV 2 (8), e319-e327, 2015 | 409 | 2015 |
